HeartVue 6S
 
The HeartVue System is an advanced technology for early, non-invasive testing of heart disease (CHD). The heart monitoring system provides high quality 3D visualization and diagnosis of the heart using advanced signal analysis. The medical device uses only 4 limb wires from the patient’s wrists and ankles. Patients are easily tested sitting up, fully clothed.

HeartVue provides a better level of diagnosis with its improved sensitivity levels that can detect early warning signs that would normally be invisible with standard ECG devices. The system will dramatically cut the costs associated with the detection of ischemic heart disease and will prove to be an invaluable testing device for cardiologists, general practitioners, physicians, clinics, hospitals, the fitness industry, sports teams and emergency facilities.
 
HeartVue depicts disease or stress levels as a 3D image supplementing the line drawing electrocardiogram. The system evaluates the stability of current heart conditions. It is highly portable and provides a rapid analysis in 30 or 60 seconds. The system will dramatically cut the costs associated with the detection of ischemic heart disease. The medical device includes software that converts the electric conductivity of the cardiac tissue into a three-dimensional, color-coded and easy-to-interpret visual portrait. This heart portrait allows physicians to observe the condition of the heart muscle and the intensity of the heart stress load quickly and easily.
 
For more information on HeartVue, including clinical documentation, demonstrations and sales queries, please get in touch with us at heartvue@efficiencytechnologies.co.uk, or call us on +44 (0) 845 299 7898
 

    

Method
 
The multiplicity of control effects and variability of receptor signals determining electrochemical phenomena in depolarization-repolarization processes of the myocardium inevitably lead to small casual ECG fluctuations with each contraction of the heart even in the state of physiological norm. The amplitudes of these fluctuations (dispersion of fluctuations) do not exceed 0.01…0.03 mV, i.e. they are several tens of times smaller than amplitudes of ECG peaks. The term "dispersion" corresponds to the generally accepted definition of difference between the maximal and minimal values of the varying quantity. In order to observe and measure the characteristics of such casual fluctuations it is necessary to plot the signals of ECG one-type peaks, i.e. synchronize the beginning of electric excitation of several successive peaks. Fig.1 and Fig.2 give examples of such low amplitude QRST fluctuations in one of the leads. Fig. 1 shows ECG low amplitude fluctuations of a healthy person, Fig.2 - in case of sub-acute stage of MI. In the cited cases one can see some characteristic amplitude and frequency peculiarities of changing fluctuations.
 
 
 
Fig1. ECG low amplitude fluctuation in successive QRSTcomplexes of a healthy heart.
          a) single complex; b) 7 successive synchronized complexes
 

Fig. 2. ECG low amplitude fluctuation in successive QRST complexes with MI.
           a) - single complex; b) 7 - successive synchronized complexes
 
Regularities of variation of such fluctuations due toinsignificance of the amplitude and casual nature were not studied in the generally accepted methods of ECG analysis. With the beginning and development of myocardial pathology dispersion characteristics begin to change earlier than ECG peaks. Therefore with control of dispersion characteristics it is possible to obtain information about developing pathology with forestalling. It is this principle that is used in HeartVue to raise sensitivity of the ECG analyzing technique under consideration to pathological changes. The unique peculiarity of dispersion characteristics is their high specificity in differentiation of norm-pathology states, i.e. HeartVue does not detect pathology in cases where there is no pathology.
 
 
Fig.3. Visual structure of the right. sections of the heart 
Fig.4. Visual structure of the left sections of the heart.
 
v - vertical axis of the heart L - longitudinal axis of the
1 - vena cava superior
2 - aorta
3 - rhythm integral indicator
4 - indicator of the state of RA myocardium (depolarization dispersion)
5 - indicator of P-Q interval anomalies
6 - indicator of stability of AB-conduction
7 - integral indicator of the state of two auricles (general characteristics conditioned by common source of excitation)
8 - indicator of final phase of RV depolarization (projection in the region of the interventricular septum)
9 - indicator of ventricular repolarization duration (correlates with Q - T)
10 - indicator of state of RV myocardium (repolarization dispersion)
11 - indicator of ventricular depolarization duration (QRS duration)
12 - indicator of state of LV myocardium (repolarization dispersion)
13 - indicator of final phase of LV depolarization
14 - indicator of state of LV myocardium (repolarization dispersion)
15 - indicator of final phase of RV depolarization (projection on posterior wall)
 
Summary 
 
 


Effectiveness of device usage

The characteristics of HeartVue considerably excel those of analogues intended for ECG screening. Suffice it to say that the time of obtaining the conclusion is 1…3 minutes, control is made without taking off clothes in the sitting position and indexes of sensitivity and specificity to ischemic heart disease increase to 80%.

For comparison: mean ECG-12 sensitivity to IHD is only 30…40%. The latter means that more than 60% of occult or pre-clinic forms of developing ischemic heart disease at present are not elicited by methods of standard ECG analysis and require applying other expensive methods of investigation (CAG, myocardial scintigraphy, etc.).
 
Advantages of the HeartVue™ 6S System compared to a traditional ECG system
The system's portability and speed of analysis add greatly to cutting the costs associated with the detection of ischemic heart disease.
 
Enables earlier detection of heart abnormalities.
 
Uses new information from ECG fluctuations that are usually ignored as "noise" by regular ECG devices.
 
The device allows a unique three dimensional color portrait of the heart's electrical field dynamics, allowing for rapid recognition and estimation of the heart's condition.
 
The HeartVue™ 6S System will depict a disease or stress level as an image instead of a line drawing electrocardiogram.
 
The Company's non-invasive screening system will provide more efficient clinical trials of new medications and treatment procedure results.
 
The system evaluates the stability of current heart conditions.
 
It improves disease-trend monitoring during medical treatment.
 
The system detects more cases of diseases and provides a better level of diagnosis with its improved sensitivity levels that can detect early warning signs that would normally be invisible with standard ECG devices. The device can detect small metabolic deviations preceding the dangerous ischemic damages of myocardium.
 
It differentiates arrhythmias and stresses.
 
Depending on the pathology, the device sensitivity surpasses standard ECG analysers by 7 - 50 times.

Ease of use makes device practical for non-clinical operators
 
 
Conclusion
 
The system will prove to be an invaluable testing device for cardiologists, general practitioners, physicians, clinics, hospitals, the fitness industry, sports teams and emergency facilities.
 
 
Contact Us
 
For more information on HeartVue, including clinical documentation, demonstrations and sales queries, please get in touch with us at heartvue@efficiencytechnologies.co.uk, or call us on +44 (0) 845 299 7898
 
Studies and Documents
 
Turkish Journal Invasive Cardiology (Moscow Institute English Translation)